2181 Stock Overview
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China.
Mabpharm Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.35|
|52 Week High||HK$1.20|
|52 Week Low||HK$0.34|
|1 Month Change||-30.00%|
|3 Month Change||-50.70%|
|1 Year Change||-63.16%|
|3 Year Change||-61.11%|
|5 Year Change||n/a|
|Change since IPO||-71.07%|
Recent News & Updates
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|2181||HK Biotechs||HK Market|
Return vs Industry: 2181 underperformed the Hong Kong Biotechs industry which returned -58.8% over the past year.
Return vs Market: 2181 underperformed the Hong Kong Market which returned -28.6% over the past year.
|2181 Average Weekly Movement||12.5%|
|Biotechs Industry Average Movement||8.3%|
|Market Average Movement||6.5%|
|10% most volatile stocks in HK Market||12.8%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 2181 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: 2181's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer.
Mabpharm Limited Fundamentals Summary
|2181 fundamental statistics|
Is 2181 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2181 income statement (TTM)|
|Cost of Revenue||CN¥11.06m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.064|
|Net Profit Margin||-864.06%|
How did 2181 perform over the long term?See historical performance and comparison